{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:48:09Z","timestamp":1788364089353,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2024.117190","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:39:01Z","timestamp":1734827941000},"page":"117190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2\/FLT3 VEN\u2013GIL hybrid single-molecule inhibitors"],"prefix":"10.1016","volume":"285","author":[{"given":"Christopher C.","family":"Goodis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Eberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinJung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt I.","family":"Civin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-8334","authenticated-orcid":false,"given":"Steven","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117190_bib1","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2024.117190_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.117190_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2024.117190_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1021\/acs.jmedchem.5b01888","article-title":"Expanding the cancer arsenal with targeted therapies: disarmament of the antiapoptotic bcl-2 proteins by small molecules","volume":"60","author":"Yap","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1098\/rsif.2006.0115","volume":"3","author":"Fletcher","year":"2006","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.ejmech.2024.117190_bib6","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117190_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.117190_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ejmech.2024.117190_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.117190_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2024.117190_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117190_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1039\/D2MD00067A","article-title":"FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms","volume":"13","author":"Acharya","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib13","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3390\/jcm12206429","article-title":"A review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2024.117190_bib14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2024.117190_bib15","unstructured":"VEN therapy: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"key":"10.1016\/j.ejmech.2024.117190_bib16","unstructured":"www.clinicaltrials.gov."},{"key":"10.1016\/j.ejmech.2024.117190_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-00958-4","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.ejmech.2024.117190_sref16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.117190_sref17","first-page":"139","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.i","volume":"13","author":"Brinton","year":"2020"},{"key":"10.1016\/j.ejmech.2024.117190_bib19","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1039\/D2MD00277A","article-title":"Discovery of N-sulfonylated aminosalicylic acids as dual MCL-1\/BCL-xL inhibitors","volume":"14","author":"Chen","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bmcl.2017.11.023","article-title":"Discovery of Mcl-1 inhibitors based on a thiazolidine-2,4-dione scaffold","volume":"28","author":"Whiting","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117190_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1476-4598-12-42","article-title":"The novel BH3 alpha-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak","volume":"12","author":"Cao","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.117190_bib23","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1039\/C5OB02063H","article-title":"Structure-based design of 3-carboxy-substituted 1,2,3,4-tetrahydroquinolines as inhibitors of myeloid cell leukemia-1 (Mcl-1)","volume":"14","author":"Chen","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib24","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1039\/c2ob07125h","article-title":"Relaxation of the rigid backbone of an oligoamide-foldamer-based \u03b1-helix mimetic: identification of potent Bcl-x L inhibitors","volume":"10","author":"Yap","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/cmdc.201500461","article-title":"Structural Re-engineering of the alpha-helix mimetic JY-1-106 into small molecules: disruption of the mcl-1-bak-BH3 protein-protein interaction with 2,6-di-substituted nicotinates","volume":"11","author":"Drennen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117190_bib26","doi-asserted-by":"crossref","first-page":"34322","DOI":"10.1039\/D3RA05711A","article-title":"Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1\/BCL-x(L) inhibitor are tolerated","volume":"13","author":"Chen","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2024.117190_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejmech.2016.02.006","article-title":"Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein","volume":"113","author":"Lanning","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/ddr.22004","article-title":"1-Sulfonylated 1,2,3,4-tetrahydroquinoline-6-carboxylic acids as simple, readily-accessible MCL-1 inhibitors","volume":"83","author":"Chen","year":"2022","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2024.117190_bib29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1021\/acsmedchemlett.5b00084","article-title":"BRD4 structure-activity relationships of dual PLK1 kinase\/BRD4 bromodomain inhibitor BI-2536","volume":"6","author":"Chen","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117190_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117680","article-title":"Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC\/non-covalent proteasome inhibitors","volume":"104","author":"Chan","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1039\/D2MD00095D","article-title":"Scaffold hopping from indoles to indazoles yields dual MCL-1\/BCL-2 inhibitors from MCL-1 selective leads","volume":"13","author":"Drennen","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/cmdc.202000278","article-title":"Rationally designed polypharmacology: alpha-helix mimetics as dual inhibitors of the oncoproteins mcl-1 and HDM2","volume":"15","author":"Conlon","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117190_bib33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2019.06.002","article-title":"Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade","volume":"178","author":"Yuan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib34","unstructured":"This PDB Corresponds to VEN Bound to the G101A Mutation of BCL-2; the Binding Is the Same as to WT BCL-2."},{"key":"10.1016\/j.ejmech.2024.117190_bib35","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1021\/acs.joc.8b02750","article-title":"Development of a convergent large-scale synthesis for venetoclax, a first-in-class BCL-2 selective inhibitor","volume":"84","author":"Ku","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105011","article-title":"The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020","volume":"113","author":"Liang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117190_bib37","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117190_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117190_bib39","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2008-07-167023","article-title":"BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3","volume":"113","author":"Nordig\u00e5rden","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.117190_bib40","doi-asserted-by":"crossref","DOI":"10.1242\/dev.177022","article-title":"PAX-SIX-EYA-DACH Network modulates GATA-FOG function in fly hematopoiesis and human erythropoiesis","volume":"147","author":"Creed","year":"2020","journal-title":"Development"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:50:16Z","timestamp":1740369016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"alternative-id":["S0223523424010729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117190","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2\/FLT3 VEN\u2013GIL hybrid single-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117190"}}